Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology

04-04-2024 | Fertility | REVIEW ARTICLE

Fertility preservation in hematological cancer patients

Authors: Dan Li, Yi-jun Zhao, Qian Wang, Man-wei Chu, Juan-ke Xie, Cui-lian Zhang

Published in: Clinical and Translational Oncology

Login to get access

Abstract

Among adolescents and young adults, hematological malignancies are the most common malignancies. Although the survival rate of hematological malignancies in young patients has been dramatically improved, due to the continuous improvement and development of tumor diagnosis and treatment options, cytotoxic therapies can significantly reduce a patient’s reproductive capacity and cause irreversible infertility. The most two established solutions are embryo cryopreservation and oocyte cryopreservation which can be considered in single female. Sperm or testicular tissue cryopreservation in adult male are feasible approaches that must be considered before gonadotoxic therapy. A comprehensive consultation with reproductive specialists when once diagnosed is a significantly issue which would help those survivors who want to have children. In this article, we review germ cell toxicity, which happens during the treatment of hematological malignancies, and aims to propose safety, efficacy fertility preservation methods in younger patients with hematological malignancies.
Literature
1.
Loren AW, Senapati S. Fertility preservation in patients with hematologic malignancies and recipients of hematopoietic cell transplants. Blood. 2019;134:746–60.CrossRefPubMed
2.
Nahata L, Caltabellotta NM, Yeager ND, Lehmann V, Whiteside SL, O’Brien SH, et al. Fertility perspectives and priorities among male adolescents and young adults in cancer survivorship. Pediatr Blood Cancer. 2018;65: e27019.CrossRefPubMed
3.
4.
5.
Blomain ES, Jiang A, Donaldson SS, Agarwal R, Bertaina A, Shyr D, et al. effect of testicular boost in children with leukemia receiving total body irradiation and stem cell transplant: A single-institution experience. Adv Radiat Oncol. 2023;8: 101071.CrossRefPubMed
6.
Zhang Y, Wang H, Pan X. Live birth in woman with premature ovarian insufficiency and 46, XY karyotype after chemotherapy and bone marrow transplant: A case report. BMC Pregnancy Childbirth. 2023;23:170.CrossRefPubMedPubMedCentral
7.
Ozdemir ZN, Bozdag SC. Hematological malignancies and fertility. Adv Exp Med Biol. 2020;1288:103–15.CrossRefPubMed
8.
Salama M, Isachenko V, Isachenko E, Rahimi G, Mallmann P. Advances in fertility preservation of female patients with hematological malignancies. Expert Rev Hematol. 2017;10:951–60.CrossRefPubMed
9.
Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25:673–93.CrossRefPubMedPubMedCentral
10.
Pampanini V, Wagner M, Asadi-Azarbaijani B, Oskam IC, Sheikhi M, Sjödin MOD, et al. Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women. Hum Reprod. 2019;34:1674–85.CrossRefPubMedPubMedCentral
11.
12.
Ashizawa M, Kanda Y. Preservation of fertility in patients with hematological malignancies. Jpn j Clin Oncol. 2020;50:729–42.CrossRefPubMed
13.
Nguyen QN, Zerafa N, Liew SH, Findlay JK, Hickey M, Hutt KJ. Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes. Mol Hum Reprod. 2019;25:433–44.CrossRefPubMed
14.
Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol. 2019;30:1760–75.CrossRefPubMed
15.
Burns KC, Hoefgen H, Strine A, Dasgupta R. Fertility preservation options in pediatric and adolescent patients with cancer. Cancer-am Cancer Soc. 2018;124:1867–76.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Salama M, Woodruff TK. Anticancer treatments and female fertility: clinical concerns and role of oncologists in oncofertility practice. Expert rev anticanc. 2017;17:687–92.CrossRef
25.
26.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Ca-Cancer J Clin. 2022;72:7–33.CrossRefPubMed
27.
Dell’Aquila K, Hodges H, Moshiri M, Katz DS, Elojeimy S, Revzin MV, et al. Imaging evaluation of lymphoma in pregnancy with review of clinical assessment and treatment options. Abdom Radiol. 2023;48:1663–78.CrossRef
28.
29.
30.
31.
Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017;23:139–55.PubMed
32.
33.
34.
35.
Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77.CrossRefPubMed
36.
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994–2001.CrossRefPubMed
37.
38.
39.
40.
41.
Ashizawa M, Akahoshi Y, Nakano H, Kawamura S, Takeshita J, Yoshino N, et al. Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Tr. 2019;25:2461–7.CrossRef
42.
Sarradin V, Simon L, Huynh A, Gilhodes J, Filleron T, Izar F. Total body irradiation using Helical Tomotherapy®: treatment technique, dosimetric results and initial clinical experience. Cancer Radiother. 2018;22:17–24.CrossRefPubMed
43.
Shi Q, Xie Y, Wang Y, Li S. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis. Sci Rep. 2017;7:8538.CrossRefPubMedPubMedCentral
44.
45.
Fasano G, Dechène J, Antonacci R, Biramane J, Vannin AS, Van Langendonckt A, et al. Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients. Reprod biomed online. 2017;34:575–82.CrossRefPubMed
46.
47.
48.
Herta AC, Lolicato F, Smitz JEJ. In vitro follicle culture in the context of IVF. Reproduction. 2018;156:F59-f73.CrossRefPubMed
49.
Khunmanee S, Park H. Three-dimensional culture for in vitro folliculogenesis in the aspect of methods and materials. Tissue Eng Part B-re. 2022;28:1242–57.CrossRef
50.
51.
52.
53.
Chen J, Todorov P, Isachenko E, Rahimi G, Mallmann P, Isachenko V. Construction and cryopreservation of an artificial ovary in cancer patients as an element of cancer therapy and a promising approach to fertility restoration. Hum Fertil. 2022;25:651–61.CrossRef
54.
55.
56.
Metadata
Title
Fertility preservation in hematological cancer patients
Authors
Dan Li
Yi-jun Zhao
Qian Wang
Man-wei Chu
Juan-ke Xie
Cui-lian Zhang
Publication date
04-04-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03419-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits